Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 4/20 | 0.62 |
| ▸ | LMNA | P02545 | 2/20 | 0.57 |
| ▸ | PYCR1 | P32322 | 1/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.48 |
| ▸ | ACHE | P22303 | 1/20 | 0.48 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | CES2 | O00748 | 1/20 | 0.46 |
| ▸ | CES1 | P23141 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL347820 | 0.84 | TSHR (0.61) | TSHRLMNAPYCR1CYP1A2CYP2D6 | |
| SCHEMBL7206952 | 0.84 | PYCR1 (0.61) | TSHRLMNAPYCR1CYP1A2CYP2D6 | |
| SCHEMBL7934234 | 0.81 | TSHR (0.57) | TSHRLMNAPYCR1CYP1A2CYP2D6 | |
| SCHEMBL10918542 | 0.80 | TSHR (0.71) | TSHRLMNAPYCR1CYP1A2CYP2D6 | |
| SCHEMBL5250015 | 0.79 | TSHR (0.65) | TSHRLMNACYP1A2CYP2D6CYP2C9 | |
| SCHEMBL29864638 | 0.79 | TSHR (0.65) | TSHRLMNACYP1A2CYP2D6CYP2C9 | |
| SCHEMBL1491377 | 0.79 | TSHR (0.59) | TSHRLMNAPYCR1CYP1A2CYP2D6 | |
| SCHEMBL94845 | 0.79 | TSHR (0.69) | TSHRLMNAPYCR1CYP1A2CYP2D6 | |
| SCHEMBL8713184 | 0.79 | TSHR (0.69) | TSHRLMNAPYCR1CYP1A2CYP2D6 | |
| SCHEMBL10651848 | 0.78 | TSHR (0.62) | TSHRLMNACYP1A2CYP2D6CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 66 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030092634-A1 | Novel compounds and compositions as protease inhibitors | AXYS PHARMACEUTICALS, INC. | 2003-05-15 | — | — | US | claimed |
| US-6506733-B1 | Which process comprises hydrogenating a compound of Formula 9: presence of a catalytic amount of 20% palladium hydroxide on carbon. | AXYS PHARMACEUTICALS, INC. | 2003-01-14 | — | — | US | claimed |
| EP-1189891-A1 | TRIAZOLE COMPOUNDS AND COMBINATORIAL LIBRARIES THEREOF | LION Bioscience AG (DE) | 2002-03-27 | — | — | EP | claimed |
| US-6362342-B1 | BIOSYNTHESIS; DRUG LIBRARIES | LION BIOSCIENCE AG (DE) | 2002-03-26 | — | — | US | claimed |
| EP-1159260-A1 | NOVEL COMPOUNDS AND COMPOSITIONS AS PROTEASE INHIBITORS | AXYS PHARMACEUTICALS, INC. (US) | 2001-12-05 | — | — | EP | claimed |
| WO-2001000594-A1 | TRIAZOLE COMPOUNDS AND COMBINATORIAL LIBRARIES THEREOF | LION BIOSCIENCE AG (DE) | 2001-01-04 | — | — | WO | claimed |
| WO-2000055124-A2 | NOVEL COMPOUNDS AND COMPOSITIONS AS PROTEASE INHIBITORS | AXYS PHARMACEUTICALS, INC. (US) | 2000-09-21 | — | — | WO | claimed |
| US-5049551-A | Antitumor | UBE INDUSTRIES, LTD. (JP) | 1991-09-17 | — | — | US | claimed |
| EP-0400610-A1 | 5-Fluorouracil derivatives | UBE INDUSTRIES, LTD. (JP) | 1990-12-05 | — | — | EP | claimed |
| US-10640761-B2 | Multivalent phage display systems and methods | UNIVERSITY OF OSLO (NO) | 2020-05-05 | — | — | US | disclosed |
| US-20170211060-A1 | MULTIVALENT PHAGE DISPLAY SYSTEMS AND METHODS | UNIVERSITY OF OSLO (NO) | 2017-07-27 | — | — | US | disclosed |
| US-9598692-B2 | Multivalent phage display systems and methods | UNIVERSITY OF OSLO (NO) | 2017-03-21 | — | — | US | disclosed |
| US-8969253-B2 | Method for screening phage display libraries against each other | NEXTERA AS (NO) | 2015-03-03 | — | — | US | disclosed |
| US-8946128-B2 | Signal sequence-independent pIX phage display | NEXTERA AS (NO) | 2015-02-03 | — | — | US | disclosed |
| US-4065618-A | Process for 3-H-3-cephem esters | ELI LILLY AND COMPANY (US) | 1977-12-27 | — | — | US | disclosed |
| US-4064343-A | ANTIBIOTICS | ELI LILLY AND COMPANY (US) | 1977-12-20 | — | — | US | disclosed |
| US-4013651-A | 3-SUBSTITUTED AMINO-CEPHALOSPORINS | ELI LILLY AND COMPANY (US) | 1977-03-22 | — | — | US | disclosed |
| US-3992377-A | 3-Thio-substituted cephalosporin antibiotics | ELI LILLY AND COMPANY (US) | 1976-11-16 | — | — | US | disclosed |
| US-3985737-A | ANTIBACTERIAL AGENTS | ELI LILLY AND COMPANY (US) | 1976-10-12 | — | — | US | disclosed |
| US-3962227-A | ANTIBIOTICS | ELI LILLY AND COMPANY (US) | 1976-06-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030092634-A1 | Novel compounds and compositions as protease inhibitors | SERPINB1, HPN, CTRL | TSHR 4781/4885LMNA 2624/4885PYCR1 2560/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.